Cargando…

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors

PURPOSE: To determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population. MATERIALS AND METHODS: Patients who were 1 to 30 years of age with relapsed/refractory solid tumors (i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vo, Kieuhoa T., Karski, Erin E., Nasholm, Nicole M., Allen, Shelly, Hollinger, Fabienne, Clay Gustafson, W., Long-Boyle, Janel R., Shiboski, Stephen, Matthay, Katherine K., DuBois, Steven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410349/ https://www.ncbi.nlm.nih.gov/pubmed/27793021 http://dx.doi.org/10.18632/oncotarget.12904

Ejemplares similares

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
por: Vo, Kieuhoa T., et al.
Publicado: (2016)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series
por: De Ioris, Maria Antonietta, et al.
Publicado: (2023)

Topotecan in the treatment of relapsed small cell lung cancer
por: Quoix, Elisabeth
Publicado: (2008)

Topotecan: An evolving option in the treatment of relapsed small cell lung cancer
por: Garst, Jennifer
Publicado: (2007)

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
por: Riemsma, Rob, et al.
Publicado: (2010)

Phase I Trial of Autologous Hematopoietic Stem Cell Transplantation with Escalating Doses of Topotecan Combined with Cyclophosphamide and Carboplatin in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma
por: Litzow, MR, et al.
Publicado: (2009)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

The combined use of sirolimus and cyclosporin in the management of refractory minimal change nephropathy: ‘a novel use of sirolimus’
por: Davison, Rachel, et al.
Publicado: (2009)

Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis
por: Namba, Masashi, et al.
Publicado: (2017)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
por: Manji, Arif, et al.
Publicado: (2022)

Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study
por: Feng, Yimei, et al.
Publicado: (2020)

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study
por: Zhang, Zhuxin, et al.
Publicado: (2023)

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
por: Penson, R T, et al.
Publicado: (2005)

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
por: Reed, Damon R., et al.
Publicado: (2015)

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results
por: Auner, Holger W., et al.
Publicado: (2022)

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
por: Shi, Haotian, et al.
Publicado: (2023)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Sirolimus in Refractory Cronkhite-Canada Syndrome and Focus on Standard Treatment
por: Langevin, Catherine, et al.
Publicado: (2018)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis
por: Imai, Hisao, et al.
Publicado: (2018)

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma
por: Lee, Seung-Shin, et al.
Publicado: (2019)

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
por: Goldsmith, Kelly C., et al.
Publicado: (2023)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
por: Abdel-Bary, N, et al.
Publicado: (2009)

P11: IXAZOMIB WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MYELOMA: MUKEIGHT PHASE II RANDOMISED CONTROLLED TRIAL RESULTS
por: Auner, H, et al.
Publicado: (2022)

Sirolimus augments hematopoietic stem and progenitor cell regeneration following hematopoietic insults
por: Lin, Zenghua, et al.
Publicado: (2020)

Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience
por: Hagmann, Raphael, et al.
Publicado: (2015)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

Infliximab for Idiopathic Deep Cutaneous Vasculitis Refractory to Cyclophosphamide
por: Schafranski, Marcelo Derbli, et al.
Publicado: (2010)

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐versus‐host disease prophylaxis
por: Hernani, Rafael, et al.
Publicado: (2021)

Association of image‐defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma
por: Temple, William C., et al.
Publicado: (2020)

Refractory Head and Neck Lymphatic Malformation in Infants Treated With Sirolimus: A Case Series
por: Wu, Changhua, et al.
Publicado: (2021)

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
por: Chiappori, Alberto A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_etclo9c6hrui9evo68iqqtsl76